Gary D Hammer on the improvement of patient care in endocrine neoplasia

IF 1.2

International Journal of Endocrine Oncology Pub Date : 2019-12-01 DOI:10.2217/ije-2019-0018

G. Hammer

引用次数: 1

Abstract

Dr Gary D Hammer is the cofounder of Millendo Therapeutics (NASDAQ, MLND, MI, USA) and the founder of Vasaragen (MI, USA), two biotechnology companies focused on rare endocrine diseases. Hammer is also an employee of the University of Michigan.

查看原文本刊更多论文

Gary D Hammer谈内分泌肿瘤患者护理的改进

Gary D Hammer博士是Millendo Therapeutics（纳斯达克，MLND，密歇根州，美国）的联合创始人和Vasaragen（密歇根州，USA）的创始人，这两家生物技术公司专注于罕见内分泌疾病。哈默也是密歇根大学的一名员工。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

International Journal of Endocrine Oncology ONCOLOGY-

自引率

0.00%

发文量

审稿时长

13 weeks

期刊介绍： International Journal of Endocrine Oncology is a quarterly, peer-reviewed journal that helps the clinician to keep up to date with best practice in this fast-moving field. The journal highlights significant advances in basic and translational research, and places them in context for future therapy. The journal presents the latest research findings in diagnosis and management of endocrine cancer, together with authoritative reviews, cutting-edge editorials and perspectives that highlight hot topics and controversy in the field. Independent drug evaluations assess newly approved medications and their role in clinical practice. The journal welcomes the unsolicited submission of article proposals and original research manuscripts.